top of page



This guide highlights the scientific background behind Laguna's therapeutic approach. Each statement links to a publication that you can access and download. If you only have time for a few papers, we think you’ll find these first few especially helpful. For additional information, please continue on.

History and safety

Listeria has a long history in the clinic

LADD is the foundational strain for Laguna Listeria

Laguna Listeria cannot grow extracellularly, which solves safety concerns from previous trials using LADD

Activation and expansion of γδ T cells

γδ T cells are exceptionally promising for immunotherapy


γδ T cells are activated and expanded through pathogen-associated molecular pattern molecules (PAMPs) and damage-associated molecular patterns (DAMPs)

In humans, γδ T cells have evolved to be exquisitely sensitive to Listeria

Other approaches are poor γ9δ2 T cell activators

Other immune cell populations have limitations for immunotherapy

Potential with other immune cells

MAIT cells are another promising immune population for immunotherapy

Biologics: mAbs and bispecifics / BiTEs

Several companies are developing γ9δ2-engaging bispecifics

Cytokine release syndrome (CRS) is a concern with biologics, but can be managed through several strategies

Graft versus host disease (GvHD) is a concern with traditional ɑβ CAR-T therapy, but is not a concern with γδ T cells


Activation + biologics combination therapy

Pre-clinical models show the potential of pairing activated γ9δ2 T cells and MAIT cells with biologics:

Activation as a monotherapy

γδ T cells that are activated and expanded by Listeria can improve outcomes for people with heme malignancies after receiving hematopoietic stem cell therapy (HSCT):

WT listeria from Dan's website - cropped.jpg
bottom of page